Figure 5
From: Potential role of miR-9 and miR-223 in recurrent ovarian cancer
TaqMan® PCR validation in training cohort and FFPE cohort. The relative quantitation from TaqMan® in recurrent vs primary tumours are plotted for both cohorts.
Figure 5 | Molecular Cancer